| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/19/2013 | CA2354638C Expression of secreted human alpha-fetoprotein in transgenic animals |
| 03/19/2013 | CA2311647C Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 03/19/2013 | CA2195334C Compositions and methods for enhanced tumor cell immunity in vivo |
| 03/14/2013 | WO2013036879A1 Compositions and methods for treating prostate cancer |
| 03/14/2013 | WO2013036866A1 Itraconazole analogs and use thereof |
| 03/14/2013 | WO2013036825A1 Methods for determining responsiveness to a dihydrofolate reductase inhibitor |
| 03/14/2013 | WO2013036799A2 Methods and compositions involving nkg2d inhibitors and cancer |
| 03/14/2013 | WO2013036720A1 Methods for treatment of cancer by targeting sirt5 |
| 03/14/2013 | WO2013036596A2 Serpinf2-binding molecules and methods of use |
| 03/14/2013 | WO2013036563A1 Pharmaceutical compositions comprising an aromatase inhibitor |
| 03/14/2013 | WO2013036294A1 Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
| 03/14/2013 | WO2013036208A1 P53 activating peptides |
| 03/14/2013 | WO2013036201A1 Polypeptide vaccine |
| 03/14/2013 | WO2013036032A1 A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
| 03/14/2013 | WO2013035931A1 Peptide inhibiting matrix metalloproteanases activity and use thereof |
| 03/14/2013 | WO2013035896A1 Novel uses of kiaa1764 as apoptosis and aging regulator |
| 03/14/2013 | WO2013035895A1 Novel apoptosis regulator |
| 03/14/2013 | WO2013035824A1 Cancer stem cell isolation |
| 03/14/2013 | WO2013035779A1 Method of analysis of intercell interactions |
| 03/14/2013 | WO2013035757A1 Preparation comprising hexose-6-phosphate-modified cholesterol derivative |
| 03/14/2013 | WO2013035641A1 Method for manufacturing block copolymer |
| 03/14/2013 | WO2013035579A1 Liver-accumulative nanoparticle having drug encapsulated therein |
| 03/14/2013 | WO2013034904A1 Anti-cd40 antibodies, uses and methods |
| 03/14/2013 | WO2013034863A1 Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
| 03/14/2013 | WO2013034741A1 Nanoparticle tumour vaccines |
| 03/14/2013 | WO2013034726A1 Nanoparticle-peptide compositions |
| 03/14/2013 | WO2013034685A1 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| 03/14/2013 | WO2013034570A1 Amino-substituted imidazopyridazines |
| 03/14/2013 | WO2013034116A1 Vascular endothelial myostatin mutant that mutates at atp binding sites |
| 03/14/2013 | WO2013033981A1 2,7-naphthyridine derivative, preparation method therefor and use thereof |
| 03/14/2013 | WO2013033961A1 Bivalent vaccine of tumor dna of prame and wt1 |
| 03/14/2013 | WO2013033862A1 4-substituted-(3-substituted-1h-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof |
| 03/14/2013 | WO2013013113A3 Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| 03/14/2013 | WO2013013075A3 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 03/14/2013 | WO2013005170A3 Inhibitors of aquaglyceroporins, methods and uses thereof |
| 03/14/2013 | WO2013005164A3 Cancer antigen |
| 03/14/2013 | WO2012173682A3 Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
| 03/14/2013 | WO2012166778A3 Conjugates of nitroimidazoles and their use as chemotherapeutic agents |
| 03/14/2013 | WO2012162089A3 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth |
| 03/14/2013 | WO2012153186A3 Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells |
| 03/14/2013 | WO2012149356A3 Anti-cd40 antibodies and methods of use |
| 03/14/2013 | WO2012145653A3 Therapeutic combinations for use in neoplasia |
| 03/14/2013 | WO2012145183A3 Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| 03/14/2013 | WO2012143477A3 Anticancer fusion protein |
| 03/14/2013 | WO2012142029A3 Serms for the treatment of estrogen receptor-mediated disorders |
| 03/14/2013 | WO2012141794A3 Crystal structure and peptide inhibitors of hausp deubiquitinase |
| 03/14/2013 | WO2012138691A3 Diagnosis and treatment of taxane-resistant cancers |
| 03/14/2013 | WO2012135528A3 Galectin-3c combination therapy for human cancer |
| 03/14/2013 | WO2012127277A3 Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| 03/14/2013 | WO2012122313A3 Targeted nanocarrier systems for delivery of actives across biological membranes |
| 03/14/2013 | WO2012079059A3 Post-treatment breast cancer prognosis |
| 03/14/2013 | WO2011128388A3 Oxazole and thiazole compounds as ksp inhibitors |
| 03/14/2013 | WO2010062171A3 Cc-1065 analogs and their conjugates |
| 03/14/2013 | US20130067608 Colon cancer targets and uses thereof |
| 03/14/2013 | US20130066069 Processes for preparing substituted pyrimidines |
| 03/14/2013 | US20130065963 Histone Deacetylase Inhibitors and Methods of Use Thereof |
| 03/14/2013 | US20130065953 Phenotypic reversion of pancreatic carcinoma cells |
| 03/14/2013 | US20130065952 Tumor-specific promoter and oncolytic virus vector comprising the same |
| 03/14/2013 | US20130065949 Microrna mirna-31 as a therapeutic approach for the treatment of cancer |
| 03/14/2013 | US20130065946 Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 |
| 03/14/2013 | US20130065945 Nlk as a marker for diagnosis of liver cancer and as a therapeutic agent thereof |
| 03/14/2013 | US20130065944 Reverse micelle system comprising nucleic acids and use thereof |
| 03/14/2013 | US20130065939 Compositions and methods for silencing genes expressed in cancer |
| 03/14/2013 | US20130065938 Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer |
| 03/14/2013 | US20130065937 Novel prenylarene compound and use thereof |
| 03/14/2013 | US20130065935 Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 |
| 03/14/2013 | US20130065933 Pharmaceutical composition for peroral administration of diindolylmethane |
| 03/14/2013 | US20130065932 Process for the isolation of organic compounds useful for the treatment of cancer |
| 03/14/2013 | US20130065928 Biomarkers for pi3k-driven cancer |
| 03/14/2013 | US20130065914 Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| 03/14/2013 | US20130065908 Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| 03/14/2013 | US20130065905 Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
| 03/14/2013 | US20130065902 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| 03/14/2013 | US20130065899 Heteroaryl compounds and uses thereof |
| 03/14/2013 | US20130065896 Fused imidazole derivative |
| 03/14/2013 | US20130065895 Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction |
| 03/14/2013 | US20130065894 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS |
| 03/14/2013 | US20130065892 Heteroaryl compounds and uses thereof |
| 03/14/2013 | US20130065890 Pyrimidine derivatives |
| 03/14/2013 | US20130065883 Triazolo [4, 5- B] Pyridin Derivatives |
| 03/14/2013 | US20130065882 VLA-4 inhibitory drug |
| 03/14/2013 | US20130065881 Tricyclic Compounds for Use as Kinase Inhibitors |
| 03/14/2013 | US20130065880 Compounds as tyrosine kinase modulators |
| 03/14/2013 | US20130065872 Synthesis of syrbactin proteasome inhibitors |
| 03/14/2013 | US20130065864 Novel iridium/rhodium anti-cancer compounds |
| 03/14/2013 | US20130065863 Nitroxyl (hno) releasing compounds and uses thereof in treating diseases |
| 03/14/2013 | US20130065862 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| 03/14/2013 | US20130065861 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| 03/14/2013 | US20130065858 Compounds useful as raf kinase inhibitors |
| 03/14/2013 | US20130065845 Triazole Compounds and Methods of Making and Using the Same |
| 03/14/2013 | US20130065841 Process for a folate-targeted agent |
| 03/14/2013 | US20130065837 Integrin interaction inhibitors for the treatment of cancer |
| 03/14/2013 | US20130065836 Biomarker for gastric cancer |
| 03/14/2013 | US20130065827 Crystalline Peptide Epoxyketone Immunoproteasome Inhibitor |
| 03/14/2013 | US20130065816 Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| 03/14/2013 | US20130064904 Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
| 03/14/2013 | US20130064902 Phosphaplatins and their use for treatment of cancers |
| 03/14/2013 | US20130064901 Gene expression profiling for classifying and treating gastric cancer |
| 03/14/2013 | US20130064889 Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof |
| 03/14/2013 | US20130064882 Compositions and Methods for the Prevention of Cancer in High Risk Patients |